Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 12 points (-0.1%) at 16,435 as of Friday, May 16, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,512 issues advancing vs. 1,401 declining with 184 unchanged.

The Health Services industry currently sits down 0.4% versus the S&P 500, which is unchanged. Top gainers within the industry include Intuitive Surgical ( ISRG), up 1.8%, CR Bard ( BCR), up 1.1%, Agilent Technologies ( A), up 1.0%, Boston Scientific ( BSX), up 0.8% and Waters ( WAT), up 0.8%. On the negative front, top decliners within the industry include Tenet Healthcare ( THC), down 1.9%, Grifols ( GRFS), down 1.9%, Community Health Systems ( CYH), down 1.7%, HCA Holdings ( HCA), down 1.2% and Humana ( HUM), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. CareFusion ( CFN) is one of the companies pushing the Health Services industry higher today. As of noon trading, CareFusion is up $0.55 (1.3%) to $42.42 on heavy volume. Thus far, 1.7 million shares of CareFusion exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $41.75-$43.13 after having opened the day at $41.75 as compared to the previous trading day's close of $41.87.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. CareFusion has a market cap of $8.5 billion and is part of the health care sector. Shares are up 5.2% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts who rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CareFusion Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Quest Diagnostics ( DGX) is up $0.46 (0.8%) to $57.97 on average volume. Thus far, 1.4 million shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $57.36-$58.08 after having opened the day at $57.51 as compared to the previous trading day's close of $57.51.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $8.3 billion and is part of the health care sector. Shares are up 7.4% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts who rate Quest Diagnostics a buy, 3 analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is up $0.95 (0.8%) to $116.50 on average volume. Thus far, 916,187 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $115.21-$116.70 after having opened the day at $115.46 as compared to the previous trading day's close of $115.55.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. Thermo Fisher Scientific has a market cap of $46.5 billion and is part of the health care sector. Shares are up 3.8% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Thermo Fisher Scientific Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null